Patents by Inventor Mary F. Fitzgerald
Mary F. Fitzgerald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170210814Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed arc the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: March 27, 2017Publication date: July 27, 2017Inventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 9629909Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: June 18, 2013Date of Patent: April 25, 2017Assignee: Domantis LimitedInventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20130309227Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: June 18, 2013Publication date: November 21, 2013Applicant: Domantis LimitedInventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Greogory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 8497244Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: January 23, 2012Date of Patent: July 30, 2013Assignee: Domantis LimitedInventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20120114651Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: January 23, 2012Publication date: May 10, 2012Inventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 8173665Abstract: The invention relates to 4-cyanophenyl, 2-sulfanyl, 1-phenyl pyrimidine derivatives, processes for their preparation, and pharmaceutical compositions of the same. Compounds and compositions of the invention are useful in the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction, and heart failure development.Type: GrantFiled: July 27, 2009Date of Patent: May 8, 2012Assignee: Bayer Pharma AktiengesellschaftInventors: Heike Gielen-Haertwig, Volkhart Min-Jian Li, Ulrich Rosentreter, Karl-Heinz Schlemmer, Swen Allerheiligen, Leila Telan, Lars Bärfacker, Jörg Keldenieh, Mary F. Fitzgerald, Kevin Nash, Barbara Albrecht, Dirk Meurer
-
Patent number: 8129503Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: October 23, 2006Date of Patent: March 6, 2012Assignee: Domantis LimitedInventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 7691854Abstract: The invention relates to novel dihydropyridine derivatives, of Formula (I) processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.Type: GrantFiled: August 18, 2003Date of Patent: April 6, 2010Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Heike Gielen-Haertwig, Volkhart Min-Jian Li, Ulrich Rosentreter, Karl-Heinz Schlemmer, Swen Allerheiligen, Leila Telan, Lars Bärfacker, Jörg Keldenich, Mary F. Fitzgerald, Kevin Nash, Barbara Albrecht, Dirk Meurer
-
Patent number: 7687510Abstract: The invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases.Type: GrantFiled: August 28, 2003Date of Patent: March 30, 2010Assignee: Bayer Healthcare AGInventors: Heike Gielen-Haertwig, Volkhart Min-Jian Li, Ulrich Rosentreter, Karl-Heinz Schlemmer, Swen Allerheiligen, Leila Telan, Lars Bärfacker, Jörg Keldenich, Mary F. Fitzgerald, Kevin Nash, Barbara Albrecht, Dirk Meurer
-
Publication number: 20100034831Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: October 23, 2006Publication date: February 11, 2010Inventors: Rudolf M.T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20100022537Abstract: This invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.Type: ApplicationFiled: July 27, 2009Publication date: January 28, 2010Applicant: Bayer Healthcare AGInventors: Heike Gielen-Haertwig, Volkhart Min-Jian Li, Ulrich Rosentreter, Karl-Heinz Schlemmer, Swen Allerheiligen, Leila Telan, Lars Bärfacker, Jörg Keldenieh, Mary F. Fitzgerald, Kevin Nash, Barbara Albrecht, Dirk Meurer
-
Patent number: 7566723Abstract: The invention relates to novel 1-Phenyl-3,4-dihydropyrimidin-2(1H)-one derivatives having the formula processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.Type: GrantFiled: August 28, 2003Date of Patent: July 28, 2009Assignee: Bayer Healthcare AGInventors: Heike Gielen-Haertwig, Volkhart Min-Jian Li, Ulrich Rosentreter, Karl-Heinz Schlemmer, Swen Allerheiligen, Leila Telan, Lars Bärfacker, Jörg Keldenich, Mary F. Fitzgerald, Kevin Nash, Barbara Albrecht, Dirk Meurer
-
Publication number: 20090111795Abstract: A compound of formula (I): M-L-M, wherein L is a linker and each M is independently a group of formula (II): is useful in therapy, e.g. of respiratory diseases.Type: ApplicationFiled: February 3, 2006Publication date: April 30, 2009Inventors: Harry Finch, Christine Edwards, Nicholas Charles Ray, Anne O'Connor, Mary F. Fitzgerald
-
Patent number: 7230017Abstract: The invention relates to novel dihydropyridinone derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.Type: GrantFiled: August 18, 2003Date of Patent: June 12, 2007Assignee: Bayer Healthcare AGInventors: Heike Gielen-Haertwig, Volkhart Min-Jian Li, Ulrich Rosentreter, Karl-Heinz Schlemmer, Swen Allerheiligen, Leila Telan, Lars Bärfacker, Jörg Keldenich, Mary F. Fitzgerald, Kevin Nash, Barbara Albrecht, Dirk Meurer
-
Patent number: 7115602Abstract: The invention relates to 7-(4-tert butyl-cyclohexyl)-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.Type: GrantFiled: May 30, 2002Date of Patent: October 3, 2006Assignee: Bayer AktiengesellschaftInventors: Cristina Alonso-Alija, Heike Gielen, Martin Hendrix, Maria Niewöhner, Dagmar Schauss, Hilmar Bischoff, Nils Burkhardt, Volker Geiss, Karl-Heinz Schlemmer, Nigel J. Cuthbert, Mary F. Fitzgerald, Graham Sturton, Ulrich Niewöhner
-
Patent number: 7087605Abstract: The invention relates to novel 5-Ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.Type: GrantFiled: May 21, 2002Date of Patent: August 8, 2006Assignee: Bayer AktiengesellschaftInventors: Cristina Alonso-Alija, Heike Gielen, Martin Hendrix, Maria Theresia Niewohner, legal representative, Dagmar Schauss, Hilmar Bischoff, Nils Burkhardt, Volker Geiss, Karl-Heinz Schlemmer, Nigel J. Cuthbert, Mary F. Fitzgerald, Richard Graham Sturton, Martin Michels, Ulrich Niewohner, deceased
-
Patent number: 7074790Abstract: The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.Type: GrantFiled: May 5, 2003Date of Patent: July 11, 2006Inventors: Cristina Alonso-Alija, Heike Gielen-Haertwig, Martin Michels, Dagmar Karthaus, Hilmar Bischoff, Nils Burkhardt, Volker Geiss, Karl-Heinz Schlemmer, Nigel Cuthbert, Mary F. Fitzgerald, Graham Sturton, Maria Theresia Niewöhner, legal representative, Ulrich Niewöhner, deceased
-
Patent number: 6900194Abstract: Novel 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives, use of substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives as Matrix Metalloprotease Inhibitors for the Treatment of Respiratory Diseases, pharmaceutical compositions containing them, and a process for using them. The compounds of the invention have the generalized formula (I) (T)xA—B—D—E—CO2H wherein A is an aryl or heteroaryl rings; B is an aryl or heteroaryl ring or a bond; each T is a substituent group, x is 0, 1, or 2; the group D represents (a), (b), (c), or (d); the group E represents a two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and each of the substituents on E is an independent substituent; and include pharmaceutically acceptable salts thereof.Type: GrantFiled: December 20, 1999Date of Patent: May 31, 2005Assignee: Bayer AktiengesellschaftInventors: Mary F. Fitzgerald, Philip J. Gardiner, Kevin Nash, Graham Sturton, Günter Benz, Rolf Henning, Karl-Heinz Schlemmer, Bernd Riedl, Helmut Haning, Lorenz Mayr
-
Publication number: 20040254187Abstract: The invention relates to novel 5-Ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.Type: ApplicationFiled: August 2, 2004Publication date: December 16, 2004Inventors: Cristina Alonso-Alija, Heike Gielen, Martin Hendrix, Ulrich Niewohner, Maria Theresia Niewohner, Dagmar Schauss, Hilmar Bischoff, Nils Burkhardt, Volker Geiss, Karl-Heinz Schlemmer, Nigel J Cuthbert, Mary F Fitzgerald, Richard Graham Sturton, Martin Michels
-
Patent number: 6677372Abstract: N-(3-benzofuranyl)urea-derivatives are prepared by reacting of 3-amino-substituted benzofuranes with appropriate substituted isocyanates or isothiocyanates. The N(3-benzofuranyl)urea-derivatives can be used as active ingredients in medicaments particularly for the treatment of acute and chronic inflammatory processes.Type: GrantFiled: May 24, 2002Date of Patent: January 13, 2004Assignee: Bayer AktiengesellschaftInventors: Gabriele Bräunlich, Rüdiger Fischer, Mazen Es-Sayed, Rolf Henning, Michael Sperzel, Karl-Heinz Schlemmer, Ulrich Nielsch, Stephen Tudhope, Graham Sturton, Trevor S. Abram, Mary F. Fitzgerald